Peter Attia MD278 ‒ Breast cancer: how to catch, treat, and survive breast cancer | Harold Burstein, M.D., Ph.D.
At a glance
WHAT IT’S REALLY ABOUT
Breast Cancer Detection, Treatment, Genetics and Care Explained by Oncologist Harold Burstein
- Burstein explains that breast cancer is the most commonly diagnosed cancer in most countries, with about a one in eight lifetime risk for American women, and that roughly 80-85% of women are cured.
- He describes three main subtypes (ER-positive/HER2-negative, HER2-positive and triple-negative) that differ in who they affect, how they are found and how they are treated.
- The conversation covers precancerous lesions such as DCIS and LCIS, where treatment options like radiation and anti-estrogens lower recurrence risk but have never been shown to change mortality, so patient preference matters greatly.
- Burstein credits both mammography screening and effective systemic therapy (anti-estrogens, trastuzumab, immunotherapy, genomic tests that spare chemotherapy, and neoadjuvant treatment) with halving breast cancer mortality each over recent decades.
- The episode closes on germline genetics (BRCA1/2, PALB2, CHEK2, ATM), multidisciplinary care, the importance of expert pathology review, and breast cancer in men.
IDEAS WORTH REMEMBERING
5 ideasPopulation-level risk factors move individual risk only modestly.
Burstein notes that factors like early menarche, fewer pregnancies, density or obesity might shift lifetime risk from about 12% to roughly 15%, unlike genetic syndromes, and smoking is not a major breast cancer risk factor.
Treating DCIS lowers recurrence but has never been shown to improve survival.
Radiation roughly halves in-breast recurrence and anti-estrogens cut it further by a few percentage points, but because DCIS is caught so early, trials are now testing whether less treatment is acceptable, and patient risk perception drives the decision.
Preventive tamoxifen offers small absolute benefits.
In the NSABP P-1 prevention trial, five years of tamoxifen cut breast cancer diagnosis from about 4% to about 2% without a survival benefit, so only highly motivated or higher-risk women tend to pursue it.
Lymph node status is the biggest prognostic marker in early breast cancer.
Staging combines tumor size, nodal involvement and tumor biology; ballpark 10-year survival is about 90% or more for stage I, 75-80% for stage II and 65-75% for stage III, while stage IV median survival is about five years.
Both early detection and better drugs have halved mortality.
Burstein attributes about half of the decline in mortality over 30-40 years to mammography and the other half to effective systemic therapy, while acknowledging ongoing debate about screening's value now that treatment has improved.
WORDS WORTH SAVING
5 quotesbreast cancer is often a disease of very healthy women, uh, women who have gone to great lengths to care for themselves, and despite that, they are encountering a breast cancer diagnosis, which is, is often frustrating.
— Harold Burstein
the analogy I give to patients all the time is this is like a colon polyp. It's a growth. It is a precancerous growth. We treat it so that it doesn't blossom into a full-blown cancer, but in and of itself, it is not a cancer lesion.
— Harold Burstein
So that is the nature of a successful screening program. You are finding precancerous lesions. The debate as it relates to breast cancer is how much treatment should we offer in these precancerous instances?
— Harold Burstein
in terms of global health, tamoxifen and other anti-estrogens have cured more w- more people of cancer than anything else we do in oncology, so aside from surgery itself.
— Harold Burstein
the quality of pathology is the foundation for all of cancer care.
— Harold Burstein
High quality AI-generated summary created from speaker-labeled transcript.
